The accelerator is returning to in-person programming after two years of virtual training, with workshops and networking spanning September and November.
MassMEDIC’s 2022 Medtech Ignite cohort startups are:
- Oxford Heartbeat, which developed the PreSize Neurovascular software to help neurovascular surgeons predict the behavior of different stent devices in an individual patient, allowing them to select the best device. Co-founder Katerina Spranger is Oxford Heartbeat’s CEO.
- BrilliantStrings Therapeutics, which developed an activated collagen biomaterial for repairing injured or degenerated connective tissue and wounds. Jeff Ruberti is CEO.
- INIA Biosciences, which develops non-invasive, home-administered, and closed-loop medical devices combining ultrasound and diagnostic sensing to manage chronic inflammatory diseases. Shen Ning is CEO.
- Synthera Health, which develops personalized care for iron deficiency and iron deficiency anemia. Heather Fraser is CEO.
“The Medtech Ignite Program accelerates the founder’s journey during the most vulnerable stage of their company’s lifecycle,” Medtech IGNITE President Rachel Robinson said in a news release. “Ignite continues to be the premier accelerator focused on development and support of the medtech start-up community in Massachusetts.
“With the goal of attracting and nurturing the next generation of Boston-area medtech founders and entrepreneurs, we are creating a pipeline of medtech startups who will help fuel the future of the Commonwealth’s medtech ecosystem by establishing offices, hiring teams, and engaging with the MassMEDIC community,” continued Robinson, who is also MassMEDIC’s chief operating officer.
Ignite’s 50 alumni startups have raised more than $100 million since MassMEDIC relaunched the program in 2019.